Randomized, double-blinded, placebo parallel-controlled phase III clinical trial to evaluate the Immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in healthy population aged 18 years and above
Latest Information Update: 02 Dec 2020
At a glance
- Drugs Coronavirus vaccine-Wuhan Institute of Biological Products (Primary)
- Indications COVID 2019 infections; COVID-19 pneumonia
- Focus Pharmacodynamics; Registrational
- Sponsors China National Biotec Group
- 02 Dec 2020 New trial record